High-throughput analysis of plasma hybrid markers for early detection of cancers

Proteomes

Volumn 2, Issue 1, 2014, Pages

  Rho, Jung hyun ^a   Lampe, Paul D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Autoantibody; Biomarker; Cancer; Early detection; Glycan; Immune complex; Plasma

Indexed keywords

EID: 84973908116     PISSN: None     EISSN: 22277382     Source Type: Journal    
DOI: 10.3390/proteomes2010001     Document Type: Review

References (84)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96
2. Church, T.R.; Black, W.C.; Aberle, D.R.; Berg, C.D.; Clingan, K.L.; Duan, F.; Fagerstrom, R.M.; Gareen, I.F.; Gierada, D.S.; Jones, G.C.; et al. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 2013, 368, 1980-1991
3. Brodersen, J.; Siersma, V.D. Long-term psychosocial consequences of false-positive screening mammography. Ann. Fam. Med. 2013, 11, 106-115
4. Croswell, J.M.; Kramer, B.S.; Kreimer, A.R.; Prorok, P.C.; Xu, J.L.; Baker, S.G.; Fagerstrom, R.; Riley, T.L.; Clapp, J.D.; Berg, C.D.; et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann. Fam. Med. 2009, 7, 212-222
5. Weller, D.; Coleman, D.; Robertson, R.; Butler, P.; Melia, J.; Campbell, C.; Parker, R.; Patnick, J.; Moss, S. The UK colorectal cancer screening pilot: Results of the second round of screening in England. Br. J. Cancer 2007, 97, 1601-1605
6. Tumor markers. Available online: http://www.Cancer.Gov/cancertopics/factsheet/detection/tumor-markers (accessed on 5 November 2013)
7. Drucker, E.; Krapfenbauer, K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013, 4, e7
8. Issaq, H.J.; Waybright, T.J.; Veenstra, T.D. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32, 967-975
9. Hori, S.S.; Gambhir, S.S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 2011, 3, 109ra116
10. Poon, T.C.; Mok, T.S.; Chan, A.T.; Chan, C.M.; Leong, V.; Tsui, S.H.; Leung, T.W.; Wong, H.T.; Ho, S.K.; Johnson, P.J. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin. Chem. 2002, 48, 1021-1027
11. Lapthorn, A.J.; Harris, D.C.; Littlejohn, A.; Lustbader, J.W.; Canfield, R.E.; Machin, K.J.; Morgan, F.J.; Isaacs, N.W. Crystal structure of human chorionic gonadotropin. Nature 1994, 369, 455-461
12. Kui Wong, N.; Easton, R.L.; Panico, M.; Sutton-Smith, M.; Morrison, J.C.; Lattanzio, F.A.; Morris, H.R.; Clark, G.F.; Dell, A.; Patankar, M.S. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 2003, 278, 28619-28634
13. Saeland, E.; Belo, A.I.; Mongera, S.; van Die, I.; Meijer, G.A.; van Kooyk, Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer 2012, 131, 117-128
14. Hanisch, F.G.; Uhlenbruck, G.; Dienst, C. Structure of tumor-associated carbohydrate antigen CA 19-9 on human seminal-plasma glycoproteins from healthy donors. Eur. J. Biochem. 1984, 144, 467-473
15. Gadroy, P.; Stridsberg, M.; Capon, C.; Michalski, J.C.; Strub, J.M.; van Dorsselaer, A.; Aunis, D.; Metz-Boutigue, M.H. Phosphorylation and O-glycosylation sites of human chromogranin a (CGA79-439) from urine of patients with carcinoid tumors. J. Biol. Chem. 1998, 273, 34087-34097
16. Wu, Y.M.; Liu, C.H.; Hu, R.H.; Huang, M.J.; Lee, J.J.; Chen, C.H.; Huang, J.; Lai, H.S.; Lee, P.H.; Hsu, W.M.; et al. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011, 71, 7270-7279
17. Liu, Y.C.; Yen, H.Y.; Chen, C.Y.; Chen, C.H.; Cheng, P.F.; Juan, Y.H.; Khoo, K.H.; Yu, C.J.; Yang, P.C.; Hsu, T.L.; et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11332-11337
18. Drapkin, R.; von Horsten, H.H.; Lin, Y.; Mok, S.C.; Crum, C.P.; Welch, W.R.; Hecht, J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162-2169
19. Pabst, M.; Bondili, J.S.; Stadlmann, J.; Mach, L.; Altmann, F. Mass + retention time = structure: A strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. Anal. Chem. 2007, 79, 5051-5057
20. Doherty, J.K.; Bond, C.; Jardim, A.; Adelman, J.P.; Clinton, G.M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. USA 1999, 96, 10869-10874
21. Majumder, S.; Brown, K.; Qiu, F.H.; Besmer, P. C-kit protein, a transmembrane kinase: Identification in tissues and characterization. Mol. Cell. Biol. 1988, 8, 4896-4903
22. Meany, D.L.; Zhang, Z.; Sokoll, L.J.; Zhang, H.; Chan, D.W. Glycoproteomics for prostate cancer detection: Changes in serum PSA glycosylation patterns. J. Proteome Res. 2009, 8, 613-619
23. Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res. 1989, 52, 257-331
24. Yang, S.X.; Pollock, H.G.; Rawitch, A.B. Glycosylation in human thyroglobulin: Location of the n-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch. Biochem. Biophys. 1996, 327, 61-70
25. Wang, V.; Li, C.; Lin, M.; Welch, W.; Bell, D.; Wong, Y.F.; Berkowitz, R.; Mok, S.C.; Bandera, C.A. Ovarian cancer is a heterogeneous disease. Cancer Genet. Cytogenet. 2005, 161, 170-173
26. Zhao, H.; Langerod, A.; Ji, Y.; Nowels, K.W.; Nesland, J.M.; Tibshirani, R.; Bukholm, I.K.; Karesen, R.; Botstein, D.; Borresen-Dale, A.L.; et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell. 2004, 15, 2523-2536
27. Warnberg, F.; Nordgren, H.; Bergkvist, L.; Holmberg, L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer 2001, 85, 869-874
28. Shah, S.P.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486, 395-399
29. Kravchenko, J.; Akushevich, I.; Seewaldt, V.L.; Abernethy, A.P.; Lyerly, H.K. Breast cancer as heterogeneous disease: Contributing factors and carcinogenesis mechanisms. Breast Cancer Res. Treat. 2011, 128, 483-493
30. West, L.; Vidwans, S.J.; Campbell, N.P.; Shrager, J.; Simon, G.R.; Bueno, R.; Dennis, P.A.; Otterson, G.A.; Salgia, R. A novel classification of lung cancer into molecular subtypes. PLoS One 2012, 7, e31906
31. Berek, J.S.; Bast, R.C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76, 2092-2096
32. Yedema, C.A.; Kenemans, P.; Wobbes, T.; Thomas, C.M.; Bon, G.G.; Mulder, C.; Voorhorst, F.J.; Verstraeten, A.A.; van Kamp, G.J.; Hilgers, J. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumor Biol. 1992, 13, 18-26
33. Firpo, M.A.; Gay, D.Z.; Granger, S.R.; Scaife, C.L.; DiSario, J.A.; Boucher, K.M.; Mulvihill, S.J. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid a in a panel screen. World J. Surg. 2009, 33, 716-722
34. Wild, N.; Andres, H.; Rollinger, W.; Krause, F.; Dilba, P.; Tacke, M.; Karl, J. A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 2010, 16, 6111-6121
35. Gormally, E.; Caboux, E.; Vineis, P.; Hainaut, P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat. Res. 2007, 635, 105-117
36. deVos, T.; Tetzner, R.; Model, F.; Weiss, G.; Schuster, M.; Distler, J.; Steiger, K.V.; Grutzmann, R.; Pilarsky, C.; Habermann, J.K.; et al. Circulating methylated sept9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 2009, 55, 1337-1346
37. Kosaka, N.; Iguchi, H.; Ochiya, T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101, 2087-2092
38. Li, T.; Kung, H.J.; Mack, P.C.; Gandara, D.R. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J. Clin. Oncol. 2013, 31, 1039-1049
39. Anderson, N.L.; Anderson, N.G. The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867
40. Catalona, W.J.; Richie, J.P.; deKernion, J.B.; Ahmann, F.R.; Ratliff, T.L.; Dalkin, B.L.; Kavoussi, L.R.; MacFarlane, M.T.; Southwick, P.C. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J. Urol. 1994, 152, 2031-2036
41. Schroder, F.H.; van der Cruijsen-Koeter, I.; de Koning, H.J.; Vis, A.N.; Hoedemaeker, R.F.; Kranse, R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000, 163, 806-812
42. Negishi, Y.; Furukawa, T.; Oka, T.; Sakamoto, M.; Hirata, T.; Okabe, K.; Matayoshi, K.; Akiya, K.; Soma, H. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Gynecol. Obstet. Invest. 1987, 23, 200-207
43. Coghlin, C.; Murray, G.I. Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics 2013, 13, 2227-2228
44. Rho, J.H.; Lampe, P.D. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays. J. Proteome Res. 2013, 12, 2311-2320
45. Soussi, T. P53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 2000, 60, 1777-1788
46. Von Mensdorff-Pouilly, S.; Petrakou, E.; Kenemans, P.; van Uffelen, K.; Verstraeten, A.A.; Snijdewint, F.G.; van Kamp, G.J.; Schol, D.J.; Reis, C.A.; Price, M.R.; et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 2000, 86, 702-712
47. Ulanet, D.B.; Torbenson, M.; Dang, C.V.; Casciola-Rosen, L.; Rosen, A. Unique conformation of cancer autoantigen b23 in hepatoma: A mechanism for specificity in the autoimmune response. Proc. Natl. Acad. Sci. USA 2003, 100, 12361-12366
48. Fourneau, J.M.; Bach, J.M.; van Endert, P.M.; Bach, J.F. The elusive case for a role of mimicry in autoimmune diseases. Mol. Immunol. 2004, 40, 1095-1102
49. Casciola-Rosen, L.; Andrade, F.; Ulanet, D.; Wong, W.B.; Rosen, A. Cleavage by granzyme b is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J. Exp. Med. 1999, 190, 815-826
50. Nozawa, K.; Fritzler, M.J.; Chan, E.K. Unique and shared features of Golgi complex autoantigens. Autoimmun. Rev. 2005, 4, 35-41
51. Rho, J.H.; Zhang, W.; Murali, M.; Roehrl, M.H.; Wang, J.Y. Human proteins with affinity for dermatan sulfate have the propensity to become autoantigens. Am. J. Pathol. 2011, 178, 2177-2190
52. Russo, N.; Wang, X.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R.C.; Tsodikov, A.; Duffy, S.; et al. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene 2011, 32, 5026-5037
53. Imahayashi, S.; Ichiyoshi, Y.; Yoshino, I.; Eifuku, R.; Takenoyama, M.; Yasumoto, K. Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer. Cancer Invest. 2000, 18, 530-536
54. Lim, K.H.; Telisinghe, P.U.; Abdullah, M.S.; Ramasamy, R. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun. 2010, 10, e3
55. Milne, K.; Kobel, M.; Kalloger, S.E.; Barnes, R.O.; Gao, D.; Gilks, C.B.; Watson, P.H.; Nelson, B.H. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009, 4, e6412
56. Nedergaard, B.S.; Ladekarl, M.; Nyengaard, J.R.; Nielsen, K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol. Oncol. 2008, 108, 106-111
57. Deschoolmeester, V.; Baay, M.; Van Marck, E.; Weyler, J.; Vermeulen, P.; Lardon, F.; Vermorken, J.B. Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010, 11, e19
58. Al-Shibli, K.I.; Donnem, T.; Al-Saad, S.; Persson, M.; Bremnes, R.M.; Busund, L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 2008, 14, 5220-5227
59. Riemann, D.; Wenzel, K.; Schulz, T.; Hofmann, S.; Neef, H.; Lautenschlager, C.; Langner, J. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int. Arch. Allergy Immunol. 1997, 114, 38-45
60. Nelson, B.H. CD20+ B cells: The other tumor-infiltrating lymphocytes. J. Immunol. 2010, 185, 4977-4982
61. Lubin, R.; Zalcman, G.; Bouchet, L.; Tredanel, J.; Legros, Y.; Cazals, D.; Hirsch, A.; Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med. 1995, 1, 701-702
62. Pedersen, J.W.; Gentry-Maharaj, A.; Nostdal, A.; Fourkala, E.O.; Dawnay, A.; Burnell, M.; Zaikin, A.; Burchell, J.; Papadimitriou, J.T.; Clausen, H.; et al. Cancer associated auto-antibodies to MUC1 and MUC4-A blinded case control study of colorectal cancer in UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Int. J. Cancer 2013, doi:10.1002/ijc.28538
63. Apweiler, R.; Hermjakob, H.; Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the swiss-prot database. Biochim. Biophys. Acta 1999, 1473, 4-8
64. Varki, A.; Kannagi, R.; Toole, B.P. Glycosylation changes in cancer. In Essentials of Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., Etzler, M.E., Eds.; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, USA, 2009
65. Brockhausen, I. Mucin-type o-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 2006, 7, 599-604
66. Adamczyk, B.; Tharmalingam, T.; Rudd, P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 2012, 1820, 1347-1353
67. Reis, C.A.; Osorio, H.; Silva, L.; Gomes, C.; David, L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 2010, 63, 322-329
68. Drake, P.M.; Cho, W.; Li, B.; Prakobphol, A.; Johansen, E.; Anderson, N.L.; Regnier, F.E.; Gibson, B.W.; Fisher, S.J. Sweetening the pot: Adding glycosylation to the biomarker discovery equation. Clin. Chem. 2009, 56, 223-236
69. Wada, Y.; Azadi, P.; Costello, C.E.; Dell, A.; Dwek, R.A.; Geyer, H.; Geyer, R.; Kakehi, K.; Karlsson, N.G.; Kato, K.; et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007, 17, 411-422
70. Yue, T.; Partyka, K.; Maupin, K.A.; Hurley, M.; Andrews, P.; Kaul, K.; Moser, A.J.; Zeh, H.; Brand, R.E.; Haab, B.B. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011, 11, 3665-3674
71. Hashii, N.; Kawasaki, N.; Itoh, S.; Nakajima, Y.; Harazono, A.; Kawanishi, T.; Yamaguchi, T. Identification of glycoproteins carrying a target glycan-motif by liquid chromatography/multiple-stage mass spectrometry: Identification of Lewis x-conjugated glycoproteins in mouse kidney. J. Proteome Res. 2009, 8, 3415-3429
72. Haab, B.B.; Yue, T. High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol. Biol. 2011, 785, 223-236
73. Yue, T.; Goldstein, I.J.; Hollingsworth, M.A.; Kaul, K.; Brand, R.E.; Haab, B.B. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 2009, 8, 1697-1707
74. Wu, Y.M.; Nowack, D.D.; Omenn, G.S.; Haab, B.B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J. Proteome Res. 2009, 8, 1876-1886
75. Yue, T.; Maupin, K.A.; Fallon, B.; Li, L.; Partyka, K.; Anderson, M.A.; Brenner, D.E.; Kaul, K.; Zeh, H.; Moser, A.J.; et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One 2011, 6, e29180
76. Rho, J.H.; Mead, J.R.; Wright, W.S.; Brenner, D.E.; Stave, J.W.; Gildersleeve, J.C.; Lampe, P.D. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J. Proteomics 2014, 96, 291-299
77. Loch, C.M.; Ramirez, A.B.; Liu, Y.; Sather, C.L.; Delrow, J.J.; Scholler, N.; Garvik, B.M.; Urban, N.D.; McIntosh, M.W.; Lampe, P.D. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol. Oncol. 2007, 1, 313-320
78. Rangiah, K.; Tippornwong, M.; Sangar, V.; Austin, D.; Tetreault, M.P.; Rustgi, A.K.; Blair, I.A.; Yu, K.H. Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J. Proteome Res. 2009, 8, 5153-5164
79. Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991, 51, 222-226
80. Beneduce, L.; Prayer-Galetti, T.; Giustinian, A.M.; Gallotta, A.; Betto, G.; Pagano, F.; Fassina, G. Detection of prostate-specific antigen coupled to immunoglobulin m in prostate cancer patients. Cancer Detect. Prev. 2007, 31, 402-407
81. Weiss, L.; Haydock, K.; Pickren, J.W.; Lane, W.W. Organ vascularity and metastatic frequency. Am. J. Pathol. 1980, 101, 101-113
82. Hittelet, A.; Camby, I.; Nagy, N.; Legendre, H.; Bronckart, Y.; Decaestecker, C.; Kaltner, H.; Nifant'ev, N.E.; Bovin, N.V.; Pector, J.C.; et al. Binding sites for Lewis antigens are expressed by human colon cancer cells and negatively affect their migration. Lab. Invest. 2003, 83, 777-787
83. Koh, Y.W.; Lee, H.J.; Ahn, J.H.; Lee, J.W.; Gong, G. Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. Am. J. Clin. Pathol. 2013, 139, 746-753
84. Remmers, N.; Anderson, J.M.; Linde, E.M.; DiMaio, D.J.; Lazenby, A.J.; Wandall, H.H.; Mandel, U.; Clausen, H.; Yu, F.; Hollingsworth, M.A. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 2013, 19, 1981-1993